SEI Investments’s Celldex Therapeutics CLDX Stock Holding History

SEI Investments’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Sell	27,780 -10,372	-27%	-$335K	﹤0.01%	2279
2026 Q1	$1.21M	Buy	+38,152	New	+$1.04M	﹤0.01%	2260
2023 Q2	–	Sell	-9,069	Closed	-$326K	–	2683
2023 Q1	$326K	Buy	9,069 +1,599	+21%	+$69K	﹤0.01%	2305
2022 Q4	$333K	Buy	+7,470	New	+$267K	﹤0.01%	2158
2019 Q2	–	Sell	-14	Closed	–	–	2448
2019 Q1	$0	Buy	+14	New	+$74	﹤0.01%	2907
2016 Q4	–	Sell	-821	Closed	-$50K	–	2925
2016 Q3	$50K	Sell	821 -196	-19%	-$12.2K	﹤0.01%	2061
2016 Q2	$67K	Sell	1,017 -139	-12%	-$8.82K	﹤0.01%	1854
2016 Q1	$66K	Sell	1,156 -1,383	-54%	-$156K	﹤0.01%	1774
2015 Q4	$597K	Sell	2,539 -3,384	-57%	-$738K	﹤0.01%	1306
2015 Q3	$937K	Buy	5,923 +3,667	+163%	+$1.04M	0.01%	1067
2015 Q2	$853K	Buy	2,256 +1,633	+262%	+$649K	0.01%	1023
2015 Q1	$260K	Sell	623 -520	-45%	-$186K	﹤0.01%	1334
2014 Q4	$313K	Buy	+1,143	New	+$284K	﹤0.01%	1275

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SEI Investments's CLDX Position: Q2 2026 in Review

SEI Investments reduced its Celldex Therapeutics (CLDX) stake by 27% in Q2 2026, selling an estimated $335K and leaving 27,780 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

SEI Investments first reported a position in CLDX in Q4 2014 and has held it in 13 quarters since. The position peaked at $1.21M in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

SEI Investments held 27,780 shares of Celldex Therapeutics worth $1.03M as of Q2 2026.
SEI Investments sold 10,372 Celldex Therapeutics shares in Q2 2026, an estimated $335K.
Celldex Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2279 holding.
SEI Investments first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 13 quarters since.
SEI Investments's Celldex Therapeutics position peaked at $1.21M in Q1 2026.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.